1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shenzhen Chipscreen Biosciences Co., Ltd.

Shenzhen Chipscreen Biosciences Co., Ltd.

688321.SS
Shenzhen Chipscreen Biosciences Co., Ltd.CN flagShanghai Stock Exchange
26.84
CNY
-0.70
- -
11.89BMarket Cap
Shenzhen Chipscreen Biosciences Co., Ltd.
688321.SS
(Shanghai Stock Exchange)

Recent

price

26.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.26
0.32
0.41
0.46
0.66
1.05
1.3
1.28
1.61
2.23
1.87
Revenue per Share
0.02
0.07
0.09
0.05
0.08
0.05
0.04
0.22
-0.28
0.13
-0.11
Basic EPS, GAAP
-0.02
-0.37
-0.33
-0.42
-0.59
-0.4
-0.88
-0.95
-0.47
-0.2
-0.57
Free Cash Flow per Basic Share
0.01
0.01
- -
- -
0.01
0.01
0.03
0.05
0.07
0.08
0.07
Dividend per Share
- -
0.08
0.89
1.03
1.01
1.05
1.08
1.3
1.01
1.11
1.08
Book Value per Share
0.39
0.87
0.82
3.3
3
2.6
2.73
2.76
2.4
2.37
2.43
Tangible Book Value per Share
330
349
360
376
410
409
407
408
408
408
408
Basic Weighted Avg Shares
85
111
148
174
269
430
530
524
658
910
762
Sales/Revenue/Turnover
1.77
24.65
19.32
6.54
7.29
3.59
3.26
-31.43
-8.39
10.95
1.94
Operating Margin (%)
4
4
4
5
11
20
39
44
59
70
- -
Depreciation Expense
5
24
31
19
31
22
17
89
-115
51
-44
Net Income, GAAP
- -
- -
3.11
6.33
14.16
- -
15.44
49.3
- -
- -
- -
Effective Tax Rate (%)
6.14
21.79
21.1
11.17
11.52
5.1
3.3
16.96
-17.41
5.6
-5.77
Profit Margin (%)
114
234
152
935
617
345
644
739
632
336
596
Working Capital
30
65
88
37
25
6
599
909
1,096
1,040
1,030
LT Debt
213
451
477
1,446
1,494
1,418
1,576
1,710
1,581
1,626
1,615
Total Equity
- -
- -
4.99
1
1.08
- -
0.73
-3.2
- -
- -
- -
Return on Invested Capital (%)
- -
- -
12.18
4.57
6.56
- -
4.14
10.02
- -
- -
- -
Return on Capital (%)
- -
- -
17.9
5.48
7.73
5.2
4.02
18.35
-24.39
11.79
-9.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
239
265
432
LT Borrowings
1,088
1,139
1,024
LT Finance Leases
8
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
408
408
408
Market Capitalization
7,592
7,393
9,691

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,083
1,135
1,246
Cash, Cash Equivalents & STI
469
502
567
Accounts Receivable, Net
160
139
207
Inventories
41
51
55
Total Current Liabilities
451
481
651
Payables & Accruals
- -
- -
- -
ST Debt
239
265
432
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.97%
2.83%
Free Cash Flow
- -
-2.81%
-57.56%
Net Income, GAAP
- -
-3%
-144.48%
Sales/Revenue/Turnover
- -
29.12%
38.32%
Total Cash Common Dividend
- -
66.64%
14.89%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
131
172
179
177
658
2025
162
244
236
- -
910
2026
257
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
- -
- -
- -
-0.28
2025
-0.05
- -
- -
- -
0.13
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.07
2025
0.02
- -
- -
- -
0.08
2026
0.02
- -
- -
- -
- -
Similar Companies
HUTCHMED (China) Limited (0013.HK)
Cann American Corp. (CNNA)
ZIM Laboratories Limited (ZIMLAB.NS)
Sumitomo Pharma Co., Ltd. (4506.T)
Allied Biotech Corporation (1780.TWO)
Pharmadrug Inc. (PHRX.CN)
Business
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) engages in the research, development, production, and commercialization of original innovative small-molecule drugs targeting unmet clinical needs in oncology, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals; its marketed products include Chidamide (Tucidinostat), an epigenetic modulator approved for peripheral T-cell lymphoma and, as of April 2024, combined with R-CHOP for previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression in China, and Chiglitazar Sodium (Carfloglitazar), a novel insulin sensitizer for type 2 diabetes; the company advances a robust pipeline featuring Chiauranib, a three-way targeted kinase inhibitor (Aurora B, CSF-1R, VEGFR, c-Kit) in phase III for advanced solid tumors, CS23546, a small-molecule PD-L1 dimer antagonist, CS231295, a brain-penetrant Aurora B selective inhibitor, CS32582, a highly selective TYK2 allosteric inhibitor for psoriasis and autoimmune conditions, CS12192, a JAK3 kinase inhibitor, and additional candidates like CS12088 and CS23074. Founded in March 2001 by senior Ph.D. experts returned from the United States and headquartered in Shenzhen, China, the company maintains a global footprint with facilities including a Chengdu regional headquarters and GMP production base, Beijing and Shanghai branches, and a U.S. subsidiary in New Jersey; it leverages an AI-assisted chemical genomics platform for drug discovery and early evaluation. Recent developments encompass expanded approvals for Chidamide in additional lymphoma indications, ongoing phase III trials for Chiauranib, phase II advancement of CS32582 for psoriasis, and a strengthened pipeline layout across five therapeutic areas to address neurodegenerative and other unmet needs, supported by over 700 global patents; the company listed as the first biopharmaceutical firm on China's STAR Market and continues global commercialization of its two marketed drugs across multiple indications in China, Japan, and Taiwan.